학술논문
Impact of Baricitinib on Patients’ Quality of Life after One Year of Treatment for Atopic Dermatitis in Real-World Practice: Results of the Observatory of Chronic Inflammatory Skin Diseases Registry.
Document Type
Article
Author
REGUIAI, Ziad; BECHEREL, Pierre André; PERROT, Jean Luc; FOUGEROUSSE, Anne Claire; BEGON, Edouard; POREAUX, Claire; BOULARD, Claire; CHABY, Guillaume; FITE, Charlotte; ZARAA, Inès; LONS-DANIC, Dominique; LIEGEON, Anne-Laure; PARIER, Josiane; QUILES-TSIMARATOS, Nathalie; DAVID, Laurene; MACCARI, François
Source
Subject
*ATOPIC dermatitis
*MEDICAL registries
*SKIN diseases
*BARICITINIB
*QUALITY of life
*
*
*
*
Language
ISSN
0001-5555
Abstract
The efficacy and safety of baricitinib for treatment of atopic dermatitis have been demonstrated in clinical trials; however, very few real-life studies have been published to date. The Observatory of Chronic Inflammatory Skin Diseases (OMCCI) registry was initiated to prospectively determine the long-term impairment caused by chronic inflammatory dermatoses on patients’ lives. The study included 88 patients starting baricitinib for treatment of atopic dermatitis. Clinical evaluation and patient-reported outcomes were recorded at baseline and after 6 and 12 months. After 6 months and 1 year of follow-up, 65 and 47 patients, respectively, were still being treated with baricitinib. Treatment failure was the main reason for discontinuation. Only 1 patient stopped baricitinib because of a side-effect. After 1 year of follow-up, the mean Eczema Area and Severity Index score decreased significantly from 20.7 to 6.4; the percentage of patients with severe atopic dermatitis decreased from 42.9% to 6.5% and a significant improvement in most patientreported outcomes was noted. There was no difference in terms of efficacy whether or not patients were previously treated with dupilumab. The results remained stable after 6 and 12 months of treatment, which suggests a sustained efficacy of the treatment in patients who initially responded well. [ABSTRACT FROM AUTHOR]